Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Limits on Light Weakly Interacting Massive Particles from the First 102.8 kg×day Data of the CDEX-10 Experiment.
Jiang H, Jia LP, Yue Q, Kang KJ, Cheng JP, Li YJ, Wong HT, Agartioglu M, An HP, Chang JP, Chen JH, Chen YH, Deng Z, Du Q, Gong H, He L, Hu JW, Hu QD, Huang HX, Li HB, Li H, Li JM, Li J, Li X, Li XQ, Li YL, Liao B, Lin FK, Lin ST, Liu SK, Liu YD, Liu YY, Liu ZZ, Ma H, Ma JL, Pan H, Ren J, Ruan XC, Sevda B, Sharma V, Shen MB, Singh L, Singh MK, Sun TX, Tang CJ, Tang WY, Tian Y, Wang GF, Wang JM, Wang L, Wang Q, Wang Y, Wu SY, Wu YC, Xing HY, Xu Y, Xue T, Yang LT, Yang SW, Yi N, Yu CX, Yu HJ, Yue JF, Zeng XH, Zeng M, Zeng Z, Zhang FS, Zhang YH, Zhao MG, Zhou JF, Zhou ZY, Zhu JJ, Zhu ZH; CDEX Collaboration. Jiang H, et al. Among authors: zeng xh, zeng m, zeng z. Phys Rev Lett. 2018 Jun 15;120(24):241301. doi: 10.1103/PhysRevLett.120.241301. Phys Rev Lett. 2018. PMID: 29956956
Search for Light Weakly-Interacting-Massive-Particle Dark Matter by Annual Modulation Analysis with a Point-Contact Germanium Detector at the China Jinping Underground Laboratory.
Yang LT, Li HB, Yue Q, Ma H, Kang KJ, Li YJ, Wong HT, Agartioglu M, An HP, Chang JP, Chen JH, Chen YH, Cheng JP, Deng Z, Du Q, Gong H, Guo QJ, He L, Hu JW, Hu QD, Huang HX, Jia LP, Jiang H, Li H, Li JM, Li J, Li X, Li XQ, Li YL, Liao B, Lin FK, Lin ST, Liu SK, Liu YD, Liu YY, Liu ZZ, Ma JL, Mao YC, Pan H, Ren J, Ruan XC, Sharma V, She Z, Shen MB, Singh L, Singh MK, Sun TX, Tang CJ, Tang WY, Tian Y, Wang GF, Wang JM, Wang L, Wang Q, Wang Y, Wang YX, Wu SY, Wu YC, Xing HY, Xu Y, Xue T, Yi N, Yu CX, Yu HJ, Yue JF, Zeng XH, Zeng M, Zeng Z, Zhang FS, Zhang YH, Zhao MG, Zhou JF, Zhou ZY, Zhu JJ, Zhu ZH; CDEX Collaboration. Yang LT, et al. Among authors: zeng xh, zeng m, zeng z. Phys Rev Lett. 2019 Nov 29;123(22):221301. doi: 10.1103/PhysRevLett.123.221301. Phys Rev Lett. 2019. PMID: 31868422
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM. He M, et al. Among authors: zeng xh. BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603. BMJ. 2024. PMID: 39442958 Free PMC article. Clinical Trial.
205 results